240 related articles for article (PubMed ID: 36765608)
1. Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs.
Forsberg EMV; Riise R; Saellström S; Karlsson J; Alsén S; Bucher V; Hemminki AE; Olofsson Bagge R; Ny L; Nilsson LM; Rönnberg H; Nilsson JA
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765608
[TBL] [Abstract][Full Text] [Related]
2. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
3. Generating CAR T cells from tumor-infiltrating lymphocytes.
Mills JK; Henderson MA; Giuffrida L; Petrone P; Westwood JA; Darcy PK; Neeson PJ; Kershaw MH; Gyorki DE
Ther Adv Vaccines Immunother; 2021; 9():25151355211017119. PubMed ID: 34159293
[No Abstract] [Full Text] [Related]
4. Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor.
Roncati L; Palmieri B
Int J Dermatol; 2020 Jul; 59(7):763-769. PubMed ID: 32441324
[TBL] [Abstract][Full Text] [Related]
5. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
6. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
7. PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.
Chen X; Zhao X; Mou X; Zhao J; Zhang Z; Zhang X; Huang J; Liu Y; Wang F; Zhang M; Wang L; Gu W; Zhang Y
Biomed Pharmacother; 2024 May; 175():116800. PubMed ID: 38788547
[TBL] [Abstract][Full Text] [Related]
8. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.
Gezgin G; Visser M; Ruano D; Santegoets SJ; de Miranda NFCC; van der Velden PA; Luyten GPM; van der Burg SH; Verdegaal EM; Jager MJ
Ophthalmol Sci; 2022 Jun; 2(2):100132. PubMed ID: 36249685
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.
Soltantoyeh T; Akbari B; Karimi A; Mahmoodi Chalbatani G; Ghahri-Saremi N; Hadjati J; Hamblin MR; Mirzaei HR
Cells; 2021 Jun; 10(6):. PubMed ID: 34207884
[TBL] [Abstract][Full Text] [Related]
11. Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function.
Ollé Hurtado M; Wolbert J; Fisher J; Flutter B; Stafford S; Barton J; Jain N; Barone G; Majani Y; Anderson J
PLoS One; 2019; 14(8):e0216373. PubMed ID: 31398192
[TBL] [Abstract][Full Text] [Related]
12. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
13. Adoptive T cell therapy for solid tumors: current landscape and future challenges.
Albarrán V; San Román M; Pozas J; Chamorro J; Rosero DI; Guerrero P; Calvo JC; González C; García de Quevedo C; Pérez de Aguado P; Moreno J; Cortés A; Soria A
Front Immunol; 2024; 15():1352805. PubMed ID: 38550594
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
16. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
Burns WR; Zhao Y; Frankel TL; Hinrichs CS; Zheng Z; Xu H; Feldman SA; Ferrone S; Rosenberg SA; Morgan RA
Cancer Res; 2010 Apr; 70(8):3027-33. PubMed ID: 20395199
[TBL] [Abstract][Full Text] [Related]
17. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
18. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy.
Katiyar V; Chesney J; Kloecker G
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509394
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
20.
Jiménez-Reinoso A; Nehme-Álvarez D; Domínguez-Alonso C; Álvarez-Vallina L
Front Oncol; 2020; 10():593848. PubMed ID: 33680923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]